Press Release: NovImmune : Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH

STOCKHOLM, Dec. 4, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi ) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the...